U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07392957) titled 'Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma' on Jan. 29.
Brief Summary: This is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma.
CTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and re...